A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs
Pharmaceutics · 25.07.2025 · 17 (8) · 967
DOI: 10.3390/pharmaceutics17080967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 25.07.2025. Verfasst von Nicole A Wilski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tavotek Biotherapeutics, 727 Norristown Road, 3 Spring House Innovation Park, Suite 101, Lower Gwynedd Township, PA 19002, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tavotek Biotherapeutics, Inc..
Abstract (Originalsprache)
Background/Objectives: All current FDA-approved antibody–drug conjugates (ADCs) are single-target and single-payload molecules that have limited efficacy in patients due to drug resistance. Therefore, our goal was to generate a novel ADC that was less susceptible to single points of resistance to reduce the likelihood of patient relapse.
Methods
We developed a dual-targeting, dual-payload ADC by conjugating a bispecific EGFR x cMET antibody to two payloads (MMAF and SN38) that had separate mechanisms of action using a novel tri-functional linker. This dual-payload ADC was tested for potency and efficacy in dividing and nondividing in vitro cell models using multiple tumor cell types. Efficacy of the dual-payload ADC was confirmed using in vivo models.
Results
Our ADC with dual MMAF and SN38 payloads was more efficacious in inhibiting cell proliferation than single-payload ADCs across multiple cancer cell lines. In addition, the dual-payload molecule inhibited nondividing cells, which were more resistant to traditional ADC payloads. The dual-payload ADC also exhibited more potent tumor growth inhibition in vivo compared to that of single-payload ADCs.
Conclusions
Overall, the bispecific antibody conjugated with both the MMAF and SN38 payloads inhibited tumor growth more strongly than ADCs conjugated with MMAF or SN38 alone. Developing dual-payload ADCs could limit the impact of acquired resistance in patients as well as lower the effective dose of each payload.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tavotek Biotherapeutics, 727 Norristown Road, 3 Spring House Innovation Park, Suite 101, Lower Gwynedd Township, PA 19002, USA.
- Tavotek Biotherapeutics, Building B, LifeBay Phase 1, 999 Yinshanhu Road, Guoxiang Street, Wuzhong District, Suzhou 215000, China.
ORCID-Profile: Nicole A Wilski
Förderung
- Tavotek Biotherapeutics, Inc.
Zitieren
APA
Wilski, N. A., Haytko, P., Zha, Z., Wu, S., Jin, Y., Chen, P., Han, C., & Chiu, M. L. (2025). A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. Pharmaceutics, 17(8), 967. https://doi.org/10.3390/pharmaceutics17080967
Vancouver
Wilski NA, Haytko P, Zha Z, Wu S, Jin Y, Chen P, et al. A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. Pharmaceutics. 2025;17(8):967. doi:10.3390/pharmaceutics17080967
BibTeX
@article{Wilski2025,
author = {Wilski, Nicole A and Haytko, Peter and Zha, Zhengxia and Wu, Simin and Jin, Ying and Chen, Peng and Han, Chao and Chiu, Mark L},
title = {A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {8},
pages = {967},
doi = {10.3390/pharmaceutics17080967}
}
EUVIMED